市場調查報告書

糖尿病性胃輕癱(DGp)- 市場洞察、流行病學、市場預測 2030年

Diabetic Gastroparesis - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 602048
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
糖尿病性胃輕癱(DGp)- 市場洞察、流行病學、市場預測 2030年 Diabetic Gastroparesis - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的糖尿病性胃輕癱(DGp)2017年的患病數估算為1,284萬3,848人,市場規模估算為13億3,970萬美元。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙)的糖尿病性胃輕癱(DGp)市場調查,市場及疾病概要,整體及各國流行病學的預測,各市場區隔的患病數的變化與預測,已上市治療藥及新藥概要,未滿足需求,各國市場規模,市場成長要素及障礙等相關資訊彙整。

目錄

第1章 重要的洞察

第2章 摘要整理

第3章 糖尿病性胃輕癱(DGp)的SWOT分析(DGp)

第4章 糖尿病性胃輕癱(DGp)市場概要

  • 市場佔有率(實在數值)
  • 市場佔有率(預測值)

第5章 疾病背景和概要

  • 簡介
  • 病因和危險因素
  • 症狀
  • 糖尿病性胃輕癱(DGp)的病因
  • 診斷
    • 臨床評分系統
    • 糖尿病性胃輕癱(DGp)的鑑別診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的總患者數

第7章 糖尿病性胃輕癱(DGp)的流行病學:各國

  • 美國
    • 假設和根據
    • 糖尿病性胃輕癱(DGp)的總患病數
    • 胃輕癱的盛行率:糖尿病各類型
    • 糖尿病性胃輕癱(DGp)的患病數:性別
    • 糖尿病性胃輕癱(DGp)的患病數:各症狀
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第8章 糖尿病性胃輕癱(DGp)的治療和管理

  • 糖尿病性胃輕癱(DGp)臨床管理的共識指南
  • 糖尿病性胃輕癱(DGp)的管理的演算法
  • 糖尿病性胃輕癱(DGp)的病患歷程

第9章 糖尿病性胃輕癱(DGp)的案例研究

第10章 未滿足需求

第11章 已上市治療藥

  • Metoclopramide:ANI Pharmaceuticals, Inc
    • 產品概要
    • 法規的里程碑
    • 其他開發活動
    • 安全性和有效性

第12章 新藥

  • Relamorelin:Allergan
    • 產品概要
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
  • Metoclopramide Nasal Spray (Gimoti):Evoke Pharma Inc.
  • Velusetrag:Theravance Biopharma
  • Sepiapterin (CNSA-001):Censa Pharmaceuticals
  • CIN-102:CinDome Pharma

第13章 其他的產品

  • TAK-954:武田藥品(Millennium Pharmaceuticals,Inc.)
    • 產品概要
    • 其他開發活動
    • 臨床開發
  • TAK-906:武田藥品(Millennium Pharmaceuticals,Inc.)
    • 安全性和有效性
  • Nimacimab:Bird Rock Bio

第14章 主要7個國家的糖尿病性胃輕癱(DGp)市場分析

  • 主要調查結果
  • 市場規模
    • 市場規模:各治療藥物

第15章 各國市場預測

  • 美國:市場預測
  • 市場規模
    • 糖尿病性胃輕癱(DGp)的整體市場規模
    • 糖尿病性胃輕癱(DGp)的市場規模:各治療藥物

第16章 歐洲5個國家的市場預測

  • 德國
    • 糖尿病性胃輕癱(DGp)的整體市場規模
    • 糖尿病性胃輕癱(DGp)的市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第17章 日本的市場預測

  • 糖尿病性胃輕癱(DGp)的整體市場規模
  • 糖尿病性胃輕癱(DGp)的市場規模:各治療藥物

第18章 與市場進入償付制度概要

第19章 市場成長要素

第20章 市場障礙

第21章 附錄

  • 參考文獻
  • 調查手法

第22章 DelveInsight的服務內容

第23章 免責聲明

第24章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0271

DelveInsight's "Diabetic Gastroparesis* - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Diabetic Gastroparesis*, historical and forecasted epidemiology as well as the Diabetic Gastroparesis* market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Diabetic Gastroparesis* market report provides current treatment practices, emerging drugs, Diabetic Gastroparesis* market share of the individual therapies, current and forecasted Diabetic Gastroparesis* market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Diabetic Gastroparesis* treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Diabetic Gastroparesis* Disease Understanding and Treatment Algorithm

The DelveInsight Diabetic Gastroparesis* market report gives a thorough understanding of the Diabetic Gastroparesis* by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Diabetic Gastroparesis*.

Treatment

It covers the details of conventional and current medical therapies available in the Diabetic Gastroparesis* market for the treatment of the condition. It also provides Diabetic Gastroparesis* treatment algorithms and guidelines in the United States, Europe, and Japan.

Diabetic Gastroparesis* Epidemiology

The Diabetic Gastroparesis* epidemiology division provide insights about historical and current Diabetic Gastroparesis* patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Diabetic Gastroparesis* epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Diabetic Gastroparesis* Epidemiology

The epidemiology segment also provides the Diabetic Gastroparesis* epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Diabetic Gastroparesis* Drug Chapters

Drug chapter segment of the Diabetic Gastroparesis* report encloses the detailed analysis of Diabetic Gastroparesis* marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Diabetic Gastroparesis* clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Diabetic Gastroparesis* treatment.

Diabetic Gastroparesis* Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Diabetic Gastroparesis* treatment.

Diabetic Gastroparesis* Market Outlook

The Diabetic Gastroparesis* market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Diabetic Gastroparesis* market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Diabetic Gastroparesis* market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Diabetic Gastroparesis* market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Diabetic Gastroparesis* market in 7MM.

The United States Market Outlook

This section provides the total Diabetic Gastroparesis* market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Diabetic Gastroparesis* market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Diabetic Gastroparesis* market size and market size by therapies in Japan is also mentioned.

Diabetic Gastroparesis* Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Diabetic Gastroparesis* market or expected to get launched in the market during the study period 2017-2030. The analysis covers Diabetic Gastroparesis* market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Gastroparesis* Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Diabetic Gastroparesis* key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Diabetic Gastroparesis* emerging therapies.

Reimbursement Scenario in Diabetic Gastroparesis*

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Diabetic Gastroparesis* domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Diabetic Gastroparesis* market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Diabetic Gastroparesis* Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Diabetic Gastroparesis*, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Diabetic Gastroparesis* epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Diabetic Gastroparesis* are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Diabetic Gastroparesis* market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diabetic Gastroparesis* market

Report Highlights

  • In the coming years, Diabetic Gastroparesis* market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Gastroparesis* R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Diabetic Gastroparesis*. Launch of emerging therapies will significantly impact the Diabetic Gastroparesis* market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Diabetic Gastroparesis*
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Diabetic Gastroparesis* Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Diabetic Gastroparesis* Pipeline Analysis
  • Diabetic Gastroparesis* Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Diabetic Gastroparesis* Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Diabetic Gastroparesis* Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Diabetic Gastroparesis* Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Diabetic Gastroparesis* market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Diabetic Gastroparesis* total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Diabetic Gastroparesis* market size during the forecast period (2017-2030)?
  • At what CAGR, the Diabetic Gastroparesis* market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Diabetic Gastroparesis* market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Diabetic Gastroparesis* market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Diabetic Gastroparesis*?
  • What is the historical Diabetic Gastroparesis* patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Diabetic Gastroparesis* in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Diabetic Gastroparesis*?
  • Out of all 7MM countries, which country would have the highest prevalent population of Diabetic Gastroparesis* during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Diabetic Gastroparesis* treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Diabetic Gastroparesis* in the USA, Europe, and Japan?
  • What are the Diabetic Gastroparesis* marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Diabetic Gastroparesis*?
  • How many therapies are developed by each company for Diabetic Gastroparesis* treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Diabetic Gastroparesis* treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Diabetic Gastroparesis* therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic Gastroparesis* and their status?
  • What are the key designations that have been granted for the emerging therapies for Diabetic Gastroparesis*?
  • What are the global historical and forecasted market of Diabetic Gastroparesis*?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Diabetic Gastroparesis* market
  • To understand the future market competition in the Diabetic Gastroparesis* market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Gastroparesis* in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Gastroparesis* market
  • To understand the future market competition in the Diabetic Gastroparesis* market

Table of Contents

1. Key Insights

2. Executive Summary of Diabetic Gastroparesis*

3. Competitive Intelligence Analysis for Diabetic Gastroparesis*

4. Diabetic Gastroparesis*: Market Overview at a Glance

  • 4.1. Diabetic Gastroparesis* Total Market Share (%) Distribution in 2017
  • 4.2. Diabetic Gastroparesis* Total Market Share (%) Distribution in 2030

5. Diabetic Gastroparesis*: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Diabetic Gastroparesis* Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Diabetic Gastroparesis* Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Diabetic Gastroparesis* Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Diabetic Gastroparesis* Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Diabetic Gastroparesis* Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Diabetic Gastroparesis* Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Diabetic Gastroparesis* Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Diabetic Gastroparesis* Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Diabetic Gastroparesis* Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Diabetic Gastroparesis* Treatment and Management
  • 8.2. Diabetic Gastroparesis* Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Diabetic Gastroparesis* Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Diabetic Gastroparesis*: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Diabetic Gastroparesis* Market Size in 7MM
  • 13.3. Diabetic Gastroparesis* Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Diabetic Gastroparesis* Total Market Size in the United States
    • 15.1.2. Diabetic Gastroparesis* Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Diabetic Gastroparesis* Total Market Size in Germany
    • 15.3.2. Diabetic Gastroparesis* Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Diabetic Gastroparesis* Total Market Size in France
    • 15.4.2. Diabetic Gastroparesis* Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Diabetic Gastroparesis* Total Market Size in Italy
    • 15.5.2. Diabetic Gastroparesis* Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Diabetic Gastroparesis* Total Market Size in Spain
    • 15.6.2. Diabetic Gastroparesis* Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Diabetic Gastroparesis* Total Market Size in the United Kingdom
    • 15.7.2. Diabetic Gastroparesis* Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Diabetic Gastroparesis* Total Market Size in Japan
    • 15.8.3. Diabetic Gastroparesis* Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Diabetic Gastroparesis*

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Diabetic Gastroparesis* Epidemiology (2017-2030)
  • Table 2 : 7MM Diabetic Gastroparesis* Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Diabetic Gastroparesis* Epidemiology in Germany (2017-2030)
  • Table 6 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Diabetic Gastroparesis* Epidemiology in France (2017-2030)
  • Table 8 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Diabetic Gastroparesis* Epidemiology in Italy (2017-2030)
  • Table 10 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Diabetic Gastroparesis* Epidemiology in Spain (2017-2030)
  • Table 12 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Diabetic Gastroparesis* Epidemiology in the UK (2017-2030)
  • Table 14 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Diabetic Gastroparesis* Epidemiology in Japan (2017-2030)
  • Table 16 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Diabetic Gastroparesis* Epidemiology (2017-2030)
  • Figure 2 : 7MM Diabetic Gastroparesis* Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Diabetic Gastroparesis* Epidemiology in the United States (2017-2030)
  • Figure 4 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Diabetic Gastroparesis* Epidemiology in Germany (2017-2030)
  • Figure 6 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Diabetic Gastroparesis* Epidemiology in France (2017-2030)
  • Figure 8 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Diabetic Gastroparesis* Epidemiology in Italy (2017-2030)
  • Figure 10 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Diabetic Gastroparesis* Epidemiology in Spain (2017-2030)
  • Figure 12 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Diabetic Gastroparesis* Epidemiology in the UK (2017-2030)
  • Figure 14 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Diabetic Gastroparesis* Epidemiology in Japan (2017-2030)
  • Figure 16 : Diabetic Gastroparesis* Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)